These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25506447)

  • 21. Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.
    Igra MS; Paling D; Wattjes MP; Connolly DJA; Hoggard N
    Br J Radiol; 2017 Jun; 90(1074):20160721. PubMed ID: 28362522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.
    Wattjes MP; Wijburg MT; van Eijk J; Frequin S; Uitdehaag BMJ; Barkhof F; Warnke C; Killestein J;
    J Neurol Neurosurg Psychiatry; 2018 May; 89(5):535-541. PubMed ID: 29142146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
    Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
    Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
    Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
    Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
    Scarpazza C; Prosperini L; Mancinelli CR; De Rossi N; Lugaresi A; Capobianco M; Moiola L; Naldi P; Imberti L; Gerevini S; Capra R
    J Neurol Sci; 2017 Jul; 378():233-237. PubMed ID: 28566170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Oshima Y; Tanimoto T; Yuji K; Tojo A
    Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
    Martí G; Río J; Rovira À; Auger C; Tintoré M; Sastre-Garriga J; Vidal A; Castilló J; Montalban X
    Rev Neurol; 2015 Feb; 60(4):164-8. PubMed ID: 25670046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Faulkner M
    Expert Opin Drug Saf; 2015; 14(11):1737-48. PubMed ID: 26394704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
    Yousry TA; Pelletier D; Cadavid D; Gass A; Richert ND; Radue EW; Filippi M
    Ann Neurol; 2012 Nov; 72(5):779-87. PubMed ID: 23280794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study.
    Pontillo G; Cocozza S; Lanzillo R; Borrelli P; De Rosa A; Brescia Morra V; Tedeschi E; Palma G
    Front Neurol; 2017; 8():294. PubMed ID: 28674518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A case of subtentorial progressive multifocal leucoencephalopathy in a patient treated with natalizumab].
    Simaniv TO; Ivanova MV; Bryukhov VV; Zakharova MN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):98-106. PubMed ID: 31156248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
    Walker A; Watson C; Alexopoulos ST; Deniz B; Arnold R; Bates D
    Curr Med Res Opin; 2014 Apr; 30(4):629-35. PubMed ID: 24289170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ
    Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
    Krämer J; Tenberge JG; Kleiter I; Gaissmaier W; Ruck T; Heesen C; Meuth SG
    PLoS One; 2017; 12(4):e0174858. PubMed ID: 28406921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.
    Honce JM; Nagae L; Nyberg E
    Mult Scler Int; 2015; 2015():809252. PubMed ID: 26483978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
    Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).
    Klotz L; Grützke B; Eveslage M; Deppe M; Gross CC; Kirstein L; Posevitz-Fejfar A; Schneider-Hohendorf T; Schwab N; Meuth SG; Wiendl H
    BMC Neurol; 2015 Jun; 15():96. PubMed ID: 26099927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.
    Wijburg MT; Witte BI; Vennegoor A; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Uitdehaag BM; Barkhof F; Killestein J; Wattjes MP
    J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1138-45. PubMed ID: 27530808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.
    Phan-Ba R; Lommers E; Tshibanda L; Calay P; Dubois B; Moonen G; Clifford D; Belachew S
    J Neurol Neurosurg Psychiatry; 2012 Feb; 83(2):224-6. PubMed ID: 22013244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.